Related Experiment Videos
Monoclonal antibodies (MAb) in clinical oncology
Abstract:
The clinical role of MAbs in the serum and immunohistochemical diagnostics is already established. Their potential usefulness for immunoscintigraphy is in the progress of evaluation and will probably be introduced in nuclear medical routine very soon. First clinical trials with special untagged or radiolabelled MAbs indicate their potency for the therapy of certain tumors. Clinical investigations with drug MAb conjugates have been started and will hopefully reveal significant therapeutic effects.
Insights
Monoclonal antibodies (MAbs) are established in diagnostics and show promise in nuclear medicine imaging. Clinical trials indicate MAbs are potent for tumor therapy and drug conjugates may offer significant therapeutic effects.
Area of Science:
- Oncology
- Immunology
- Nuclear Medicine
Background:
- Monoclonal antibodies (MAbs) have a proven track record in serum and immunohistochemical diagnostics.
- The application of MAbs in immunoscintigraphy is currently under evaluation for routine nuclear medicine use.
Purpose of the Study:
- To evaluate the current and emerging clinical applications of monoclonal antibodies (MAbs).
- To highlight the potential of MAbs in diagnostics, imaging, and therapy of tumors.
Main Methods:
- Review of established diagnostic roles of MAbs.
- Assessment of ongoing evaluations for immunoscintigraphy applications.
- Analysis of preliminary clinical trial data for MAb-based tumor therapy.
Main Results:
- Monoclonal antibodies (MAbs) are clinically validated for serum and immunohistochemical diagnostics.
- Immunoscintigraphy with MAbs is progressing towards routine nuclear medicine integration.
- Early clinical trials demonstrate the efficacy of MAbs in treating specific tumors.
Conclusions:
- Monoclonal antibodies (MAbs) are expanding from diagnostics to advanced nuclear medicine applications.
- MAbs show significant therapeutic potential for various cancers, with ongoing research into drug conjugates.